Hong Kong Stock Alert | SIHUAN PHARM (00460) Surges Over 9% as Subsidiary's Semaglutide Injection Application Accepted by NMPA

Stock News

Aug 18

SIHUAN PHARM (00460) surged over 9%, and as of press time, the stock was up 7.69% to HK$1.54 with a trading volume of HK$113 million.

On the news front, SIHUAN PHARM announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with type 2 diabetes.

Additionally, the Phase III clinical trial enrollment for semaglutide injection's weight loss indication has been completed and is currently in the follow-up stage.

It is reported that the diabetes field represents a key strategic focus for Huisheng Biopharmaceutical. The acceptance of this semaglutide injection marketing application by the NMPA marks another significant milestone in the drug's development process, which will help further enhance the core competitiveness of both the group and Huisheng Biopharmaceutical in the diabetes treatment sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1141083258"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141083258\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141083258?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141083258","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Alert | SIHUAN PHARM (00460) Surges Over 9% as Subsidiary's Semaglutide Injection Application Accepted by NMPA","media":"Stock News","content":"<p>SIHUAN PHARM (00460) surged over 9%, and as of press time, the stock was up 7.69% to HK$1.54 with a trading volume of HK$113 million.</p>\n<p>On the news front, SIHUAN PHARM announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with type 2 diabetes.</p>\n<p>Additionally, the Phase III clinical trial enrollment for semaglutide injection's weight loss indication has been completed and is currently in the follow-up stage.</p>\n<p>It is reported that the diabetes field represents a key strategic focus for Huisheng Biopharmaceutical. The acceptance of this semaglutide injection marketing application by the NMPA marks another significant milestone in the drug's development process, which will help further enhance the core competitiveness of both the group and Huisheng Biopharmaceutical in the diabetes treatment sector.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | SIHUAN PHARM (00460) Surges Over 9% as Subsidiary's Semaglutide Injection Application Accepted by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | SIHUAN PHARM (00460) Surges Over 9% as Subsidiary's Semaglutide Injection Application Accepted by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-18 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIHUAN PHARM (00460) surged over 9%, and as of press time, the stock was up 7.69% to HK$1.54 with a trading volume of HK$113 million.</p>\n<p>On the news front, SIHUAN PHARM announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with type 2 diabetes.</p>\n<p>Additionally, the Phase III clinical trial enrollment for semaglutide injection's weight loss indication has been completed and is currently in the follow-up stage.</p>\n<p>It is reported that the diabetes field represents a key strategic focus for Huisheng Biopharmaceutical. The acceptance of this semaglutide injection marketing application by the NMPA marks another significant milestone in the drug's development process, which will help further enhance the core competitiveness of both the group and Huisheng Biopharmaceutical in the diabetes treatment sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1600","symbol_name":"工业大麻","start_time":0,"source_url":"","article_id":"1141083258","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141083258","pubTimestamp":1755481595,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIHUAN PHARM (00460) surged over 9%, and as of press time, the stock was up 7.69% to HK$1.54 with a trading volume of HK$113 million. On the news front, SIHUAN PHARM announced that the marketing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1600":"工业大麻","BK1515":"抗疫概念","00460":"四环医药","BK1191":"制药","BK1593":"医美概念股"},"translate_title":"港股快讯|四环医药(00460)大涨超9%子公司司美格鲁肽注射液申请获NMPA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"SIHUAN PHARM (00460) surged over 9%, and as of press time, the stock was up 7.69% to HK$1.54 with a trading volume of HK$113 million.\nOn the news front, SIHUAN PHARM announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with type 2 diabetes.\nAdditionally, the Phase III clinical trial enrollment for semaglutide injection's weight loss indication has been completed and is currently in the follow-up stage.\nIt is reported that the diabetes field represents a key strategic focus for Huisheng Biopharmaceutical. The acceptance of this semaglutide injection marketing application by the NMPA marks another significant milestone in the drug's development process, which will help further enhance the core competitiveness of both the group and Huisheng Biopharmaceutical in the diabetes treatment sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}